At the news
? BULLISHIMPACT 7/10 8-K filed Jun 3, 2026 at 09:04 ET
Axsome settled all SUNOSI patent litigation, granting five generic companies entry rights no earlier than March 2040 (or September 2040 with pediatric exclusivity). This removes a major overhang and secures SUNOSI's exclusivity for over 14 years, significantly de-risking the product's long-term revenue stream.
- All outstanding SUNOSI patent litigation resolved via settlement with the only remaining first-to-file generic applicant.
- Five companies granted the right to sell generic SUNOSI beginning on or after September 1, 2040 (if pediatric exclusivity granted) or March 1, 2040 (if not), subject to FDA approval.
- No other SUNOSI patent litigation remains pending.
- Settlement will be submitted to FTC and DOJ for review.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access